Abstract
We evaluated serum levels of soluble fragments of cytokeratin 19 (CYFRA 21‐1) by immunoassay (ES‐700; Roche Diagnostics, Mannheim, Germany) to assess its usefulness in the diagnosis and follow‐up of bladder cancer. The study included 39 patients with a diagnosis of transitional cell carcinoma (group 1) and 190 patients (group 2) with no evidence of tumor. In group 2, 180 patients had a history of bladder cancer, and 10 had benign prostatic hyperplasia. Significant differences in CYFRA 21‐1 concentrations between groups 1 and 2 (P<0.01) were noted. However, CYFRA 21‐1 levels did not significantly differ between the patients with benign prostatic hyperplasia and those with bladder cancer (P=0.274). CYFRA 21‐1 values were higher in invasive bladder cancer compared to that detected in superficial stages (P=0.011). Setting the optimal cutoff value at 2.5 ng/mL resulted in a sensitivity of 43.6% and a specificity of 82.1%. No statistical differences were found when we compared disease‐free time among the 66 patients with recurrences (30.7 months with levels <2.5 ng/mL vs. 41.2 months with levels >2.5 ng/mL; P=0.248). The risk of recurrence in patients with levels lower than 2.5 ng/mL (0.79) was no different (P=0.097) from that found in patients with higher levels (1.69). CYFRA 21‐1 serum levels do not provide enough sensitivity to justify its application in routine protocols for the detection and follow‐up of bladder cancer. J. Clin. Lab. Anal. 19:167–171, 2005. © 2005 Wiley‐Liss, Inc.
Keywords: CYFRA 21‐1, serum, bladder cancer, diagnosis, follow‐up
REFERENCES
- 1. Messing EM. Urothelial tumors of the urinary tract In: Walsh PC, Retik AB, Vaughn ED, et al., editors. Campbell's urology. 8th ed Philadelphia: W.B Saunders; 2002. p 2732–2773. [Google Scholar]
- 2. Newling DW. Preventing recurrence and progression in superficial bladder cancer. Curr Opin Urol 1996;6:272–279. [Google Scholar]
- 3. Badalament RA, Hemansen DK, Kimmel M, et al. The sensitivity of bladder cancer wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 1987;60:1423–1427. [DOI] [PubMed] [Google Scholar]
- 4. Grossman HB. New methods for detection of bladder cancer. Semin Urol Oncol 1998;16:17–22. [PubMed] [Google Scholar]
- 5. Soloway MS. Do we have a prostate specific antigen for bladder cancer? J Urol 1999;161:447–448. [DOI] [PubMed] [Google Scholar]
- 6. Ozen H, Craig‐Hall M. Bladder cancer. Curr Opin Oncol 1999;11:207–212. [DOI] [PubMed] [Google Scholar]
- 7. Ross JS, Cohen MB. Detecting recurrent bladder cancer: new methods and biomarkers. Expert Rev Mol Diagn 2001;1:39–52. [DOI] [PubMed] [Google Scholar]
- 8. Fuchs E. Keratins as biochemical markers of epithelial differentiation. Trends Genet 1988;4:277–281. [DOI] [PubMed] [Google Scholar]
- 9. Bodenmüller H. The biochemistry of CYFRA 21‐1 and other cytokeratin‐tests. Scand J Clin Lab Invest 1995;55:60–66. [DOI] [PubMed] [Google Scholar]
- 10. American Joint Committee on Cancer . AJCC manual for staging of cancer. 3rd ed Philadelphia: Lippincott‐Raven Publishers; 1988. p 194–195. [Google Scholar]
- 11. Morita T, Kikuchi T, Hashimoto S, Kobayashi Y, Tokue A. Cytokeratin‐19 fragment (CYFRA 21‐1) in bladder cancer. Eur Urol 1997;32:237–244. [PubMed] [Google Scholar]
- 12. van der Gaast A, Schoenmakers CH, Kok TC, Blijenberg BG, Cornillie F, Splinter TA. Evaluation of a new tumor marker in patients with non‐small cell lung cancer: CYFRA 21‐1. Br J Cancer 1994;69:525–528. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Mady EA. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21‐1, TPA and TPS. Int J Biol Markers 2001;16:130–135. [DOI] [PubMed] [Google Scholar]
- 14. Stieber P, Schemeller N, Schambeck C, et al. Clinical relevance of CYFRA 21‐1, TPA‐IRMA and TPA‐LIA‐mat in urinary bladder cancer. Anticancer Res 1996;16:3793–3798. [PubMed] [Google Scholar]
- 15. Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D. Evaluation of urine CYFRA 21‐1 for the detection of primary and recurrent bladder carcinoma. Cancer 2002;94:2914–2922. [DOI] [PubMed] [Google Scholar]
- 16. Pariente JL, Bordenave L, Jacob F, et al. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer. J Urol 2000;163:1116–1119. [PubMed] [Google Scholar]
- 17. Dittadi R, Barioli P, Gion M, et al. Standardization of assay for cytokeratin‐related tumor marker CYFRA 21‐1 in urine samples. Clin Chem 1996;42:1634–1638. [PubMed] [Google Scholar]
- 18. Niklinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Laudanski J. Diagnostic and prognostic value of the new tumor marker CYFRA 21‐1 in patients with squamous cell lung cancer. Eur Respir J 1995;8:291–296. [DOI] [PubMed] [Google Scholar]
- 19. Sanchez‐Carbayo M, Urrutia M, Silva JM, Romani R, De Buitrago JM, Navajo JA. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21‐1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001;165:1462–1467. [PubMed] [Google Scholar]
- 20. Maier U, Simak R, Neuhold N. The clinical value of urinary cytology: 12 years of experience with 615 patients. J Clin Pathol 1995;48:314–317. [DOI] [PMC free article] [PubMed] [Google Scholar]